Market closed
Sagimet Biosciences Inc/$SGMT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sagimet Biosciences Inc
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
Ticker
$SGMT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
14
Website
SGMT Metrics
BasicAdvanced
$101M
-
-$1.45
-
-
Price and volume
Market cap
$101M
52-week high
$4.24
52-week low
$1.73
Average daily volume
582K
Financial strength
Current ratio
34.3
Quick ratio
33.958
Total debt to equity
0.05
Management effectiveness
Return on assets (TTM)
-26.49%
Return on equity (TTM)
-36.92%
Valuation
Price to book
0.65
Price to tangible book (TTM)
0.65
Price to free cash flow (TTM)
-2.327
Growth
Earnings per share change (TTM)
-45.46%
3-year earnings per share growth (CAGR)
-80.61%
SGMT News
AllArticlesVideos
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
GlobeNewsWire·2 months ago
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
GlobeNewsWire·2 months ago
Sagimet Biosciences' Denifanstat Should Be Worth More Today
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Sagimet Biosciences Inc stock?
Sagimet Biosciences Inc (SGMT) has a market cap of $101M as of April 27, 2025.
What is the P/E ratio for Sagimet Biosciences Inc stock?
The price to earnings (P/E) ratio for Sagimet Biosciences Inc (SGMT) stock is 0 as of April 27, 2025.
Does Sagimet Biosciences Inc stock pay dividends?
No, Sagimet Biosciences Inc (SGMT) stock does not pay dividends to its shareholders as of April 27, 2025.
When is the next Sagimet Biosciences Inc dividend payment date?
Sagimet Biosciences Inc (SGMT) stock does not pay dividends to its shareholders.
What is the beta indicator for Sagimet Biosciences Inc?
Sagimet Biosciences Inc (SGMT) does not currently have a Beta indicator.